JAT to exhibit in-house brands at world’s largest trade fair
ASX supply chain play, JAT Energy (ASX:JAT), has secured exhibition space at the 18th Shanghai International Children Baby and Maternity Products Industry Expo, which will take place from July 25-27.
JAT is a China-Australia cross-border specialist in Fast Moving Consumer Goods (FMCG) exports. The company develops in-house brands for Australian products for sale offline and online, with a focus on the Chinese market — especially milk products.
JAT’s 18 square metre exhibition space will showcase its rapidly expanding portfolio of in-house products, including:
- Premium Infant Formula (Stage I for newborns to six months)
- Premium Follow-On Formula (Stage II for six to twelve months)
- Premium Toddler Milk Drink (Stage III for one to three years)
- Full Cream Instant Milk Powder
- Lactoferrin Milk Powder
- DHA Algae Oil Softgel
Golden Koala and NEURIO product samples and information will be made available to visitors; brochures will also outline the range of products Cobbitty Country plans to release in the coming months.
JAT will be supported by Shanghai Dragon Corporation staff in both the exhibition space and at private meetings with agents, distributors, wholesalers and retailers.
JAT executive director, Wilton Yao, said: “These trade fairs offer excellent brand exposure. More importantly, visitors are trade professionals looking for new products and new suppliers and planning to place orders.”
Yao noted that JAT’s exhibition space is ideally situated in the ‘Australia’ pavilion, adjacent to the ‘Fabulous Mom Zone’.
However it is an early stage of this company’s development and if considering this stock for your portfolio you should take all public information into account and seek professional financial advice.
The CBME China 2017 Post-Show Report showed that almost all visitors were professional buyers, while 89 per cent of visitors attended with the purpose of placing orders, as shown below:
This pleasing development comes on a veritable wave of newsflow from JAT. Last week, JAT revealed that JD Global, China’s largest retailer by revenue, has approved the sale of Sunnya’s Neurio-branded products (Sunnya is one of JAT’s subsidiaries). The Neurio range will be sold to Chinese consumers on JD Global’s cross-border and supermarket platforms, www.JD.com and JD.hk.
Only days before that — and in the wake of a deftly engineered distribution deal with Cyclone E-Commerce for over $7.5 million in single product revenue — JAT also announced that its subsidiary, Golden Koala Group, has developed a new OPO formula for milk products for the Australian and overseas markets.
This all seemed to meet shareholder approval, given that JAT is on an upward trajectory, currently up 12.1 per cent, sitting at 7.4 cents.
Past performance is not necessarily indicative of future results. As part of the due diligence process, clients must consider all factors over and above the past performance of the product. Clients should not engage with a product solely on it past performance.
When the experts at Next Investors have a stock pick, it may pay to listen.
The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.
They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.
Click the link below to see what they are currently investing in.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.